Sales Performance - Total sales for Q4 2025 were $79.4 million, up from $66.0 million in Q4 2024, representing a growth of approximately 20.5%[6] - Total sales for fiscal year 2025 were $282.8 million, an increase from $237.9 million in fiscal year 2024, reflecting a growth of approximately 18.8%[13] - Sales for the three months ended August 31, 2025, increased to $79,448,000, up 20.4% from $66,012,000 in the same period of 2024[33] Profitability - Adjusted net income for Q4 2025 was $2.5 million, or $0.20 per diluted share, compared to $1.0 million, or $0.09 per diluted share in Q4 2024, marking a 150% increase[8] - Net loss for fiscal year 2025 was $1.9 million, or $(0.16) per diluted share, significantly improved from a net loss of $8.8 million, or $(0.79) per diluted share in fiscal year 2024[14] - Net income for the three months ended August 31, 2025, was $2,273,000, compared to a net loss of $5,201,000 in the same period of 2024[33] - The company reported an operating income of $1,464,000 for the three months ended August 31, 2025, compared to a loss of $5,805,000 in the same period of 2024[33] Operating Metrics - Restaurant-level operating profit for Q4 2025 was $15.7 million, or 19.8% of sales, compared to $13.8 million, or 20.9% of sales in Q4 2024[12] - Restaurant-level operating profit for the three months ended August 31, 2025, was $15,698,000, with a margin of 19.8%, slightly down from 20.9% in 2024[42] - Comparable restaurant sales increased by 0.2% in Q4 2025, driven by a traffic increase of 0.5% and a price/mix decrease of 0.3% compared to Q4 2024[6] - Comparable restaurant sales performance for the three months ended August 31, 2025, was 0.2%, a recovery from a decline of 3.1% in the same period of 2024[34] Expenses and Efficiency - General and administrative expenses as a percentage of sales decreased to 11.7% in Q4 2025 from 20.3% in Q4 2024, primarily due to sales leverage and reduced litigation expenses[10] - General and administrative expenses for the three months ended August 31, 2025, decreased to $9,288,000 from $13,416,000 in 2024, improving efficiency[38] Future Projections and Expansion - For fiscal year 2026, the company projects total sales between $330 million and $334 million, with plans to open 16 new restaurants[17] - The company opened a record of 15 new locations during fiscal year 2025, contributing to its expansion strategy[5] Asset Growth - Total assets as of August 31, 2025, rose to $430,942,000, up from $328,522,000 in 2024, indicating strong asset growth[35] - Total stockholders' equity increased to $231,070,000 as of August 31, 2025, compared to $162,538,000 in 2024, reflecting improved financial health[35] EBITDA - Adjusted EBITDA for fiscal year 2025 was $19.1 million, compared to $14.6 million in fiscal year 2024, indicating a growth of approximately 30.8%[15] - Adjusted EBITDA for the twelve months ended August 31, 2025, was $19,065,000, a significant increase from $14,564,000 in 2024, reflecting a margin improvement to 6.7% from 6.1%[40]

Clinical Trials and Product Development - The company is advancing its lead in vivo programs, lonvo-z and nex-z, which are the only Phase 3 genome editing product candidates targeting hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively [118]. - The Phase 3 HAELO study for lonvo-z has enrolled 60 adults, with a primary endpoint of reducing HAE attacks from week 5 to week 28, and topline data is expected by mid-2026 [122]. - A single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, with all 10 patients remaining attack-free for a median of nearly two years [123]. - The FDA placed a clinical hold on the IND applications for nex-z due to a report of Grade 4 liver transaminase elevations in a patient, with an ongoing investigation into the case [126]. - More than 650 patients with ATTR-CM are currently enrolled in the MAGNITUDE trial, with Grade 4 liver transaminase elevations reported in less than 1% of patients [127]. - The MAGNITUDE trial aims to evaluate the efficacy and safety of nex-z in adults with ATTR-CM, with a primary endpoint focused on cardiovascular-related mortality and events [129]. - The MAGNITUDE Phase 3 clinical trial is currently on hold due to reports of Grade 4 liver transaminase elevations and increased total bilirubin [132]. - Nex-z is subject to a co-development and co-promotion agreement with Regeneron, which shares approximately 25% of worldwide development costs and commercial profits for the ATTR program [136]. Financial Performance - Collaboration revenue increased by $4.7 million to $13.8 million for the three months ended September 30, 2025, compared to $9.1 million for the same period in 2024 [143]. - Research and development expenses decreased by $28.6 million to $94.7 million for the three months ended September 30, 2025, compared to $123.4 million for the same period in 2024, representing a 23% reduction [145]. - Operating loss improved by $33.3 million to $(111.5) million for the three months ended September 30, 2025, compared to $(144.8) million for the same period in 2024 [143]. - Net loss decreased by $34.4 million to $(101.3) million for the three months ended September 30, 2025, compared to $(135.7) million for the same period in 2024 [143]. - Collaboration revenue for the nine months ended September 30, 2025, decreased by $0.3 million to $44.7 million compared to $45.0 million for the same period in 2024 [151]. - Total operating expenses decreased by $55.9 million to $386.9 million for the nine months ended September 30, 2025, compared to $442.8 million for the same period in 2024 [151]. - Interest income decreased by $14.5 million to $22.7 million for the nine months ended September 30, 2025, compared to $37.2 million for the same period in 2024 [151]. - Research and development expenses decreased by $49.2 million to $300.2 million for the nine months ended September 30, 2025, a 14% decline compared to $349.4 million in the same period of 2024 [153]. - External development expenses for the Nex-z program increased by $15.8 million, a 31% rise, while Lonvo-z expenses rose by $6.7 million, a 21% increase [153]. - General and administrative expenses decreased by $6.7 million, primarily due to a reduction in stock-based compensation [154]. - Other income increased by $17.7 million, mainly due to a $32.1 million change in the fair value of investments, partially offset by a $14.5 million decrease in interest income [155]. - As of September 30, 2025, the company had $669.9 million in cash, cash equivalents, and marketable securities [157]. - Net cash used in operating activities was $325.5 million for the nine months ended September 30, 2025, compared to $263.7 million in the same period of 2024 [165]. - Net cash provided by financing activities was $129.5 million during the nine months ended September 30, 2025, including $128.2 million from at-the-market offerings [170]. Strategic Direction and Future Outlook - The company aims to transform the lives of patients with severe diseases by developing potentially curative genome editing treatments [116]. - The company expects to fund ongoing operating expenses and capital requirements into mid-2027, based on current cash and collaboration funding [163]. - A strategic reorganization in January 2025 is expected to decrease expenses as the company focuses on high-value programs like Lonvo-z and Nex-z [159]. - The company anticipates a decrease in expenses due to a workforce reduction and a strategic shift in research and development focus [161].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission file number: 001-35593 HOMETRUST BANCSHARES, INC. (Exact name of registrant as specified in its charter) Maryland 45-5055422 (State or other jurisdic ...

Financial Overview - As of September 30, 2025, the company managed approximately $771 billion in total capital, including $209 billion in assets under management (AUM) and $562 billion in assets under advisement (AUA) [214]. - The company generated $125 billion in AUM from separately managed accounts (SMAs) and $68 billion from focused commingled funds as of September 30, 2025 [216]. - Advisory relationships accounted for $562 billion of AUA and $16 billion of AUM as of September 30, 2025 [220]. - The company provided portfolio analytics and reporting on over $829 billion of client commitments through its proprietary SPI Reporting as of September 30, 2025 [220]. - As of September 30, 2025, the company had over $100 billion of performance fee-eligible capital across over 225 programs [251]. - Assets Under Management (AUM) was $209 billion as of September 30, 2025, up from $176 billion as of September 30, 2024 [333]. - Assets related to advisory accounts were $562 billion as of September 30, 2025, compared to $506 billion as of September 30, 2024 [334]. - Fee-Earning AUM (FEAUM) increased approximately $5.6 billion to $132.8 billion as of September 30, 2025, compared to June 30, 2025 [335]. - FEAUM increased by approximately $11.4 billion to $132.8 billion as of September 30, 2025, compared to March 31, 2025 [336]. Exchange and Ownership - The company completed the 2025 Exchange, acquiring approximately 5% of the equity interests of SRA, SRE, and SPD, resulting in ownership of approximately 60% of SRA and SRE, and 59% of SPD [236]. - The aggregate consideration paid in the 2025 Exchange was approximately $10 million in cash, 756,105 shares of Class A common stock, and 2,438,403 Class D units [236]. Employee and Operational Insights - The company has over 1,240 total employees, including 420 investment professionals, as of September 30, 2025 [215]. - The company operates in 31 cities across 19 countries, enhancing client relationships through local staffing and regional insights [215]. Revenue and Income - Total revenues increased by $182.5 million, or 67%, to $454.2 million for the three months ended September 30, 2025, compared to the same period in 2024 [288]. - Management and advisory fees, net rose by $30.7 million, or 17%, to $215.5 million for the three months ended September 30, 2025, driven by new client activity and a 27% growth in average FEAUM [289]. - Realized carried interest allocation revenues surged by $41.2 million, or 234%, to $58.9 million for the three months ended September 30, 2025, reflecting higher realization activity within private equity funds [291]. - Net income (loss) attributable to StepStone Group Inc. was $(366.1) million for the three months ended September 30, 2025, compared to $17.6 million in the same period of 2024 [290]. - Adjusted revenues increased by $89.9 million, or 21%, to $519.8 million for the six months ended September 30, 2025, compared to the same period in 2024 [355]. - Adjusted net income (ANI) increased by $4.4 million, or 4%, to $115.2 million for the six months ended September 30, 2025, compared to the same period in 2024 [356]. Expenses and Compensation - Total expenses increased by $956.3 million, or 433%, to $1,177.0 million for the three months ended September 30, 2025, primarily due to increases in equity-based compensation and performance fee-related compensation [298]. - Equity-based compensation rose by $847.1 million to $884.5 million for the three months ended September 30, 2025, mainly due to increased expenses for liability classified awards related to profits interest [300]. - Total performance fee-related compensation expense increased by $83.2 million, or 228%, to $119.7 million for the three months ended September 30, 2025, reflecting the increase in carried interest allocation revenue [301]. - Cash-based compensation includes salaries, bonuses, employee benefits, and cash-based incentive awards [259]. - Approximately 50% of carried interest allocation revenue is awarded to employees as performance fee-related compensation, fostering alignment of interest with clients and investors [260]. Market and Economic Factors - The company continues to monitor macroeconomic factors, including inflation and geopolitical tensions, which may impact financial markets and its business operations [225]. - The company highlighted that market conditions and investment opportunities may differ from past experiences, potentially impacting future performance [376]. Cash Flow and Debt - The company generated $62.5 million in net cash from operating activities for the six months ended September 30, 2025, compared to $103.9 million for the same period in 2024 [390]. - The company used $21.6 million in net cash for investing activities for the six months ended September 30, 2025, compared to $34.1 million in 2024 [391]. - Financing activities provided $43.4 million in net cash for the six months ended September 30, 2025, compared to a net cash used of $(23.6) million in 2024 [391]. - The company had $269.9 million in debt obligations as of September 30, 2025, net of debt issuance costs [386]. - The weighted-average interest rate for the Revolver as of September 30, 2025, was 6.40% [393]. - The company has a credit agreement with a revolving facility of $300.0 million, maturing in May 2029 [392]. Dividends - The company announced a dividend of $0.28 per share of Class A common stock, payable on December 15, 2025 [410]. - Total dividends paid in FY2025 amounted to $1.08 per share of Class A common stock [411]. - Total dividends paid in FY2026 to date amounted to $0.92 per share of Class A common stock [411].

Financial Performance - vTv Therapeutics reported a net loss of $8.7 million or $1.08 per basic share for Q3 2025, compared to a net loss of $4.8 million or $0.88 per basic share in Q3 2024[6]. - Total operating expenses for Q3 2025 were $10.7 million, compared to $6.5 million in Q3 2024[10]. - vTv Therapeutics' accumulated deficit reached $319.55 million as of September 30, 2025, compared to $299.72 million at the end of 2024[8]. Cash Position - The company's cash position increased to $98.5 million as of September 30, 2025, up from $36.7 million at the end of 2024[5]. - The total liabilities increased to $28.95 million as of September 30, 2025, from $23.97 million at the end of 2024[8]. Research and Development - Research and development expenses rose to $7.0 million in Q3 2025, compared to $3.2 million in Q3 2024, reflecting increased spending on cadisegliatin and other projects[6]. - vTv Therapeutics successfully completed an $80 million private placement in September 2025 to fund the ongoing CATT1 Phase 3 trial[5]. - The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025, with topline data expected in the second half of 2026[5]. - The company anticipates reporting topline results from the CATT1 trial in the second half of 2026[2]. Intellectual Property - The U.S. Patent and Trademark Office allowed claims for a new patent covering crystalline forms of cadisegliatin, with exclusivity expected until 2041[5].

Financial Performance - Total revenue for Q3 2025 was $5.847 billion, an increase from $5.478 billion in Q2 2025[4] - Net income for Q3 2025 was $1.471 billion, or $2.70 per share, compared to $1.345 billion, or $2.46 per share in Q2 2025[4] - Operating income decreased from $8.1 billion in 2024 to $5.4 billion in 2025[45] - Net income for 2024 was $6.4 billion, declining to $4.3 billion in 2025[45] - Reported Net Income (GAAP) for Q3 2025 was $1,824 million, resulting in an Adjusted Net Income (Non-GAAP) of $1,821 million, with diluted earnings per share of $2.71[60] - For Q2 2025, Reported Net Income (GAAP) was $1,751 million, leading to an Adjusted Net Income (Non-GAAP) of $1,649 million, with diluted earnings per share of $2.32[62] - In Q1 2025, Reported Net Income (GAAP) was $1,877 million, with an Adjusted Net Income (Non-GAAP) of $2,031 million, resulting in diluted earnings per share of $2.87[64] - For FY 2024, Reported Net Income (GAAP) was $8,218 million, while Adjusted Net Income (Non-GAAP) reached $8,477 million, with diluted earnings per share of $11.62[67] Cash Flow and Expenditures - Generated $1.4 billion in free cash flow and returned nearly $1.0 billion to shareholders through dividends and share repurchases[5][8] - Cash Operating Costs for Q3 2025 were $2.00 per Boe, an increase from $1.80 per Boe in Q2 2025[1] - Total Cash Operating Costs per Boe for Q3 2025 were $20.27, slightly higher than $20.25 in Q2 2025[71] - Net Cash Provided by Operating Activities (GAAP) for 2025 was $7,432 million, with Adjusted Cash Flow from Operations (Non-GAAP) at $8,340 million[78] - Free Cash Flow (Non-GAAP) for 2025 totaled $3,685 million, reflecting strong operational performance[78] - The company incurred $5,967 million in net cash used in investing activities for the year 2024[50] - The company reported a total of $12,143 million in net cash provided by operating activities for the year 2024[50] Production and Operations - Crude oil production reached 534.5 MBod, exceeding the guidance midpoint of 532.4 MBod[6][22] - In Q3 2025, total crude oil and condensate volumes reached 534.5 MBod, exceeding guidance by 2.1 MBod and up from 504.2 MBod in Q2 2025[33] - Natural gas liquids volumes totaled 309.3 MBbld, surpassing guidance by 4.3 MBbld, and significantly increased from 258.4 MBbld in Q2 2025[33] - Total crude oil equivalent volumes were 1,301.2 MBoed, exceeding guidance by 7.9 MBoed, and up from 1,134.1 MBoed in Q2 2025[33] - The company expects natural gas volumes in the U.S. for Q4 2025 to be between 2,740 MMcfd and 2,840 MMcfd, with a midpoint of 2,790 MMcfd[34] - For Q4 2025, crude oil and condensate volumes are guided to be between 542.5 MBod and 547.5 MBod, with a midpoint of 545.0 MBod[34] Capital Expenditures and Investments - Capital expenditures for Q3 2025 totaled $1.648 billion, slightly below the guidance midpoint of $1.650 billion[6] - The guidance for total capital expenditures for FY 2025 is between $6,200 million and $6,400 million, with a midpoint of $6,300 million[34] - The company made significant investments in oil and gas properties, totaling $5,353 million for the year 2024[50] - Total Capital Expenditures (Non-GAAP) for FY 2023 were $6,041 million, compared to $4,607 million in FY 2022, marking a 31% increase[80] Debt and Equity - Net debt increased to $4.164 billion, with a net debt-to-total capitalization ratio of 12.1%[4] - The net debt-to-total capitalization ratio was reported at 30%[45] - Long-term debt increased significantly from $3,757 million in March 2024 to $7,667 million by September 2025, indicating a rise of 104.8%[49] - Debt-to-Total Capitalization (GAAP) ratio increased to 20.3% in September 2025 from 12.7% in June 2025[82] Market Conditions and Risks - The average benchmark price for WTI crude oil was $64.95 per barrel, compared to $71.42 in Q2 2025, reflecting a decrease of 9.3%[33] - EOG's future financial position and performance are subject to risks including commodity price fluctuations and operational costs[1] - The company anticipates benefits from the acquisition of Encino, although integration risks exist[1] - The effective income tax rate for Q3 2025 was 19.4%, lower than the guidance of 20.5%[33] Shareholder Returns - The company declared a regular dividend of $1.02 per share, representing an indicated annual rate of $4.08 per share[10] - EOG committed to returning 89% of its estimated annual free cash flow to shareholders, with potential for additional returns[8] - The company declared dividends of $2.97 per share for 2025, compared to $3.70 per share in 2024[45]

Revenue and Growth - Total revenues for the three months ended September 30, 2025, were $42,049,000, representing a 67.5% increase from $25,094,000 in the same period of 2024[4] Expenses and Losses - Operating expenses for the nine months ended September 30, 2025, totaled $179,706,000, compared to $134,431,000 for the same period in 2024, reflecting a 33.6% increase[4] - The net loss for the nine months ended September 30, 2025, was $54,063,000, a decrease from a net loss of $92,082,000 in the same period of 2024, indicating a 41.2% improvement[4] - The company incurred $60,956,000 in stock-based compensation for the nine months ended September 30, 2025, compared to $23,292,000 for the same period in 2024, representing a 161.5% increase[6] - Cash flows used in operating activities for the nine months ended September 30, 2025, were $76,336,000, slightly higher than $75,755,000 for the same period in 2024[6] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $268,936,000, up from $198,240,000 as of December 31, 2024, showing a 35.4% increase[2] - The total assets increased to $702,217,000 as of September 30, 2025, compared to $553,953,000 as of December 31, 2024, marking a 26.8% growth[2] Liabilities and Capital - The total liabilities decreased to $302,981,000 as of September 30, 2025, down from $371,300,000 as of December 31, 2024, reflecting a 18.4% reduction[2] - The company reported a significant increase in additional paid-in capital, rising to $1,396,094,000 as of September 30, 2025, from $1,125,470,000 as of December 31, 2024, which is a 24% increase[2] Financing Activities - The net cash provided by financing activities for the nine months ended September 30, 2025, was $204,514,000, compared to $115,445,000 for the same period in 2024, indicating a 77% increase[6]

SUPPLEMENTAL FINANCIAL INFORMATION FOR THREE MONTHS ENDED SEPTEMBER 30, 2025 November 6, 2025 60 Cutter Mill Rd., Great Neck, NY 11021 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Exhibit 99.1 We consider some of the information set forth herein to contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, with respect to our expect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION American Coastal Insurance Corporation (Exact Name of Registrant as Specified in its Charter) WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35761 (State or Other J ...

Financial Performance - Lifecore Biomedical recorded $31.1 million in revenue for the three months ended September 30, 2025, representing a 26% increase from $24.7 million in the comparable prior period[11] - The company achieved a gross profit of $7.8 million, up from $5.4 million in the prior year, driven by a $4.3 million increase in HA manufacturing gross profit[13] - Total revenues for the three months ended September 30, 2025, were $31,109,000, a 25.9% increase from $24,705,000 for the same period in 2024[35] - Gross profit for the same period was $7,791,000, compared to $5,387,000 in the prior year, reflecting a 44.6% increase[35] - Adjusted EBITDA for the three months ended September 30, 2025, was $3,050,000, a significant improvement from a loss of $1,793,000 in the same period of 2024[38] - Lifecore's Adjusted EBITDA for the period was $3.1 million, an increase of $4.9 million compared to a negative $1.8 million in the prior year[16] - The net loss for the three months ended September 30, 2025, was $9,991,000, an improvement from a net loss of $16,230,000 in the same period of 2024[35] - Estimated net loss for the seven-month transition period from May 26, 2025, to December 31, 2025, is projected to be between $18,400,000 and $16,400,000[40] Cost Management - Selling, general and administrative expenses decreased by $5.9 million to $8.9 million compared to $14.8 million in the prior period, reflecting cost management efforts[14] - The company plans to launch a new ERP system in Q1 2026 to enhance inventory control and financial management, contributing to cost reduction[12] Operational Efficiency - Lifecore has improved workforce productivity in manufacturing by over 20% over the past year, reflecting its commitment to operational efficiency[12] - The company is focused on maximizing existing customer business and advancing late-stage development programs towards commercialization[3] Future Outlook - The company expects revenue for the transition period from May 26 to December 31, 2025, to be approximately $74 to $76 million, with a net loss projected between $18.4 million and $16.4 million[19] - Lifecore aims for a revenue CAGR of 12%+ and adjusted EBITDA margins exceeding 25% over the mid-term[3] - The company aims to achieve a revenue CAGR of over 12% and increase Adjusted EBITDA margins to more than 25% in the mid-term[30] Balance Sheet - The current assets as of September 30, 2025, totaled $83,928,000, slightly down from $85,677,000 as of May 25, 2025[33] - The total liabilities as of September 30, 2025, were $198,418,000, compared to $191,909,000 as of May 25, 2025[33] - The company reported a weighted average of 37,402,912 shares outstanding for the three months ended September 30, 2025[35] Corporate Changes - The company plans to transition its fiscal year end to align with the calendar year, effective for the December 31, 2025, period[39] - Lifecore signed two new programs during the quarter, including one late-stage and one early-stage program, expanding its service capabilities beyond ophthalmic therapeutics[6]